Does EPA Lower CV Risk? REDUCE-IT Revisited
After years of controversy, both skeptics and proponents of the REDUCE-IT study findings agree that a new trial may be desirable, but unlikely to happen.
Source: medscape.com
Page 37 - Ipid Management News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Ipid Management. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Ipid Management Today - Breaking & Trending Today
Recount of FOURIER Data Finds Higher Mortality With Evolocumab
A readjudication of mortality data from the FOURIER trial by outside researchers concludes CV death was higher with evolocumab than originally reported. But FOURIER trialists stand by their conclusions.
Source: medscape.com
Low Bone Hormone Tied to Worse Cardiac Risk in Type 2 Diabetes
Age- and sex-related differences in the relationship between levels of a bone-derived hormone, osteocalcin, and cardiometabolic risk factors are apparent in study of patients with type 2 diabetes.
Source: medscape.com
PCSK9 Inhibition Likely Doesn't Promote HF: Genetic Study
A large case-control study using genetic proxies for PCSK9 inhibitors may help alleviate concerns that the dyslipidemia agents could promote adverse cardiac remodeling and heart failure.
Source: medscape.com
Not All Children With Type 2 Diabetes Have Obesity
As many as one in four children who have type 2 diabetes do not have obesity, a new meta-analysis found.
Source: medscape.com